Recurrent Glioblastoma Multiforme Treatment Market - Global Outlook and Forecast 2021-2027

Code: RW00014561094
Market Monitor Global
Oct-2021
Life Sciences
104 Pages

This report contains market size and forecasts of Recurrent Glioblastoma Multiforme Treatment in Global, including the following market information:
Global Recurrent Glioblastoma Multiforme Treatment Market Revenue, 2016-2021, 2022-2027, ($ millions)
Global top five companies in 2020 (%)
The global Recurrent Glioblastoma Multiforme Treatment market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Recurrent Glioblastoma Multiforme Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recurrent Glioblastoma Multiforme Treatment Market, By Type, 2016-2021, 2022-2027 ($ millions)
Global Recurrent Glioblastoma Multiforme Treatment Market Segment Percentages, By Type, 2020 (%)
AU-105
Axitinib
AXL-1717
AZD-7451
Others

China Recurrent Glioblastoma Multiforme Treatment Market, By Application, 2016-2021, 2022-2027 ($ millions)
China Recurrent Glioblastoma Multiforme Treatment Market Segment Percentages, By Application, 2020 (%)
Hospital
Clinic
Others

Global Recurrent Glioblastoma Multiforme Treatment Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)
Global Recurrent Glioblastoma Multiforme Treatment Market Segment Percentages, By Region and Country, 2020 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Total Recurrent Glioblastoma Multiforme Treatment Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)
Total Recurrent Glioblastoma Multiforme Treatment Market Competitors Revenues Share in Global, by Players 2020 (%)
Further, the report presents profiles of competitors in the market, including the following:
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cantex Pharmaceuticals, Inc.
Cavion LLC
Celldex Therapeutics, Inc.
Coherus BioSciences, Inc.
Cortice Biosciences, Inc.
Eisai
Eli Lilly and Company
EnGeneIC Ltd
ERC Belgium SA
GenSpera, Inc.
Genzyme Corporation
GW Pharmaceuticals Plc
ImmunoCellular Therapeutics, Ltd.

Table of Contents

1 Introduction to Research & Analysis Reports
1.1 Recurrent Glioblastoma Multiforme Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Recurrent Glioblastoma Multiforme Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Recurrent Glioblastoma Multiforme Treatment Overall Market Size
2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size: 2021 VS 2027
2.2 Global Recurrent Glioblastoma Multiforme Treatment Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Recurrent Glioblastoma Multiforme Treatment Players in Global Market
3.2 Top Global Recurrent Glioblastoma Multiforme Treatment Companies Ranked by Revenue
3.3 Global Recurrent Glioblastoma Multiforme Treatment Revenue by Companies
3.4 Top 3 and Top 5 Recurrent Glioblastoma Multiforme Treatment Companies in Global Market, by Revenue in 2020
3.5 Global Companies Recurrent Glioblastoma Multiforme Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Recurrent Glioblastoma Multiforme Treatment Players in Global Market
3.6.1 List of Global Tier 1 Recurrent Glioblastoma Multiforme Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Recurrent Glioblastoma Multiforme Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Recurrent Glioblastoma Multiforme Treatment Market Size Markets, 2021 & 2027
4.1.2 AU-105
4.1.3 Axitinib
4.1.4 AXL-1717
4.1.5 AZD-7451
4.1.6 Others
4.2 By Type - Global Recurrent Glioblastoma Multiforme Treatment Revenue & Forecasts
4.2.1 By Type - Global Recurrent Glioblastoma Multiforme Treatment Revenue, 2016-2021
4.2.2 By Type - Global Recurrent Glioblastoma Multiforme Treatment Revenue, 2022-2027
4.2.3 By Type - Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Recurrent Glioblastoma Multiforme Treatment Market Size, 2021 & 2027
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application - Global Recurrent Glioblastoma Multiforme Treatment Revenue & Forecasts
5.2.1 By Application - Global Recurrent Glioblastoma Multiforme Treatment Revenue, 2016-2021
5.2.2 By Application - Global Recurrent Glioblastoma Multiforme Treatment Revenue, 2022-2027
5.2.3 By Application - Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2016-2027
6 Sights by Region
6.1 By Region - Global Recurrent Glioblastoma Multiforme Treatment Market Size, 2021 & 2027
6.2 By Region - Global Recurrent Glioblastoma Multiforme Treatment Revenue & Forecasts
6.2.1 By Region - Global Recurrent Glioblastoma Multiforme Treatment Revenue, 2016-2021
6.2.2 By Region - Global Recurrent Glioblastoma Multiforme Treatment Revenue, 2022-2027
6.2.3 By Region - Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share, 2016-2027
6.3 North America
6.3.1 By Country - North America Recurrent Glioblastoma Multiforme Treatment Revenue, 2016-2027
6.3.2 US Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.3.3 Canada Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.3.4 Mexico Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.4 Europe
6.4.1 By Country - Europe Recurrent Glioblastoma Multiforme Treatment Revenue, 2016-2027
6.4.2 Germany Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.4.3 France Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.4.4 U.K. Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.4.5 Italy Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.4.6 Russia Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.4.7 Nordic Countries Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.4.8 Benelux Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.5 Asia
6.5.1 By Region - Asia Recurrent Glioblastoma Multiforme Treatment Revenue, 2016-2027
6.5.2 China Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.5.3 Japan Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.5.4 South Korea Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.5.5 Southeast Asia Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.5.6 India Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.6 South America
6.6.1 By Country - South America Recurrent Glioblastoma Multiforme Treatment Revenue, 2016-2027
6.6.2 Brazil Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.6.3 Argentina Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Revenue, 2016-2027
6.7.2 Turkey Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.7.3 Israel Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.7.4 Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
6.7.5 UAE Recurrent Glioblastoma Multiforme Treatment Market Size, 2016-2027
7 Players Profiles
7.1 Boehringer Ingelheim GmbH
7.1.1 Boehringer Ingelheim GmbH Corporate Summary
7.1.2 Boehringer Ingelheim GmbH Business Overview
7.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.1.4 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.1.5 Boehringer Ingelheim GmbH Key News
7.2 Boston Biomedical, Inc.
7.2.1 Boston Biomedical, Inc. Corporate Summary
7.2.2 Boston Biomedical, Inc. Business Overview
7.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.2.4 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.2.5 Boston Biomedical, Inc. Key News
7.3 Bristol-Myers Squibb Company
7.3.1 Bristol-Myers Squibb Company Corporate Summary
7.3.2 Bristol-Myers Squibb Company Business Overview
7.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.3.4 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.3.5 Bristol-Myers Squibb Company Key News
7.4 Cantex Pharmaceuticals, Inc.
7.4.1 Cantex Pharmaceuticals, Inc. Corporate Summary
7.4.2 Cantex Pharmaceuticals, Inc. Business Overview
7.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.4.4 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.4.5 Cantex Pharmaceuticals, Inc. Key News
7.5 Cavion LLC
7.5.1 Cavion LLC Corporate Summary
7.5.2 Cavion LLC Business Overview
7.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.5.4 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.5.5 Cavion LLC Key News
7.6 Celldex Therapeutics, Inc.
7.6.1 Celldex Therapeutics, Inc. Corporate Summary
7.6.2 Celldex Therapeutics, Inc. Business Overview
7.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.6.4 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.6.5 Celldex Therapeutics, Inc. Key News
7.7 Coherus BioSciences, Inc.
7.7.1 Coherus BioSciences, Inc. Corporate Summary
7.7.2 Coherus BioSciences, Inc. Business Overview
7.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.4.4 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.7.5 Coherus BioSciences, Inc. Key News
7.8 Cortice Biosciences, Inc.
7.8.1 Cortice Biosciences, Inc. Corporate Summary
7.8.2 Cortice Biosciences, Inc. Business Overview
7.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.8.4 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.8.5 Cortice Biosciences, Inc. Key News
7.9 Eisai
7.9.1 Eisai Corporate Summary
7.9.2 Eisai Business Overview
7.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.9.4 Eisai Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.9.5 Eisai Key News
7.10 Eli Lilly and Company
7.10.1 Eli Lilly and Company Corporate Summary
7.10.2 Eli Lilly and Company Business Overview
7.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.10.4 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.10.5 Eli Lilly and Company Key News
7.11 EnGeneIC Ltd
7.11.1 EnGeneIC Ltd Corporate Summary
7.11.2 EnGeneIC Ltd Business Overview
7.11.3 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.11.4 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.11.5 EnGeneIC Ltd Key News
7.12 ERC Belgium SA
7.12.1 ERC Belgium SA Corporate Summary
7.12.2 ERC Belgium SA Business Overview
7.12.3 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.12.4 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.12.5 ERC Belgium SA Key News
7.13 GenSpera, Inc.
7.13.1 GenSpera, Inc. Corporate Summary
7.13.2 GenSpera, Inc. Business Overview
7.13.3 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.13.4 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.13.5 GenSpera, Inc. Key News
7.14 Genzyme Corporation
7.14.1 Genzyme Corporation Corporate Summary
7.14.2 Genzyme Corporation Business Overview
7.14.3 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.14.4 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.14.5 Genzyme Corporation Key News
7.15 GW Pharmaceuticals Plc
7.15.1 GW Pharmaceuticals Plc Corporate Summary
7.15.2 GW Pharmaceuticals Plc Business Overview
7.15.3 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.15.4 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.15.5 GW Pharmaceuticals Plc Key News
7.16 ImmunoCellular Therapeutics, Ltd.
7.16.1 ImmunoCellular Therapeutics, Ltd. Corporate Summary
7.16.2 ImmunoCellular Therapeutics, Ltd. Business Overview
7.16.3 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Major Product Offerings
7.16.4 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Revenue in Global (2016-2021)
7.16.5 ImmunoCellular Therapeutics, Ltd. Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Recurrent Glioblastoma Multiforme Treatment Market Opportunities & Trends in Global Market
Table 2. Recurrent Glioblastoma Multiforme Treatment Market Drivers in Global Market
Table 3. Recurrent Glioblastoma Multiforme Treatment Market Restraints in Global Market
Table 4. Key Players of Recurrent Glioblastoma Multiforme Treatment in Global Market
Table 5. Top Recurrent Glioblastoma Multiforme Treatment Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Recurrent Glioblastoma Multiforme Treatment Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Recurrent Glioblastoma Multiforme Treatment Revenue Share by Companies, 2016-2021
Table 8. Global Companies Recurrent Glioblastoma Multiforme Treatment Product Type
Table 9. List of Global Tier 1 Recurrent Glioblastoma Multiforme Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Recurrent Glioblastoma Multiforme Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type

Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cantex Pharmaceuticals, Inc.
Cavion LLC
Celldex Therapeutics, Inc.
Coherus BioSciences, Inc.
Cortice Biosciences, Inc.
Eisai
Eli Lilly and Company
EnGeneIC Ltd
ERC Belgium SA
GenSpera, Inc.
Genzyme Corporation
GW Pharmaceuticals Plc
ImmunoCellular Therapeutics, Ltd.

First Name *

Last Name

Country *

E-mail *

Contact No *

Company Name*

Job Title*

Comments

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Have a Question?

EMAIL US

RELATED PRODUCTS

ReportsWeb has an extensive coverage of industry reports, company reports and country reports accross all industries.

View All New Reports

Global Freckle-removing Medical and Beau.. The global market for Freckle-removing Medical and Beauty Eq..

Global Wall Mounted Sinks Market Growth .. The sink is a trough-shaped appliance used to receive kitche..

Global Peripheral Imaging Catheter Marke.. The Peripheral Imaging Catheter's unique design provides exc..

Global Hemostatic Valves and Accessories.. Haemostatic valve prevents blood reflux when a catheter is i..

Global Liver Cancer Treatment Drug Marke.. The global market for Liver Cancer Treatment Drug is estimat..

Global Hypertensive Heart Disease Drug M.. The global market for Hypertensive Heart Disease Drug is est..

Global Urinary Incontinence Drug Market .. The global market for Urinary Incontinence Drug is estimated..

Global Pet Antibiotic Market Growth 2022.. The global market for Pet Antibiotic is estimated to increas..

Global Hemorrhagic Disease Detection Mar.. The global market for Hemorrhagic Disease Detection is estim..

Global Cell Dissociation Solution Market.. The global market for Cell Dissociation Solution is estimate..

Global Cell Detachment and Dissociation .. The global market for Cell Detachment and Dissociation Solut..

Global Cell Detachment Solution Market G.. The global market for Cell Detachment Solution is estimated ..

CUSTOM RESEARCH

ReportsWeb has an extensive coverage of industry reports, company reports and country reports accross all industries.

LEARN MORE